연구동향 분석

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer

김동완 김범석 김태민 허대석 이준구 김영주 이세훈 2015년

논문상세정보
인용/피인용
' The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • anaplastic lymphoma kinase
  • epidermalgrowthfactorreceptor
  • healthcarecosts
  • non-small cell lung carcinoma
  • protein kinase inhibitors
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,313 0

0.0%

' The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer' 의 참고문헌

  • The cost of illness handbook
    Bouwes N. U.S. Environmental Protection Agency
  • Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma
    de Perrot M J Thorac Cardiovasc Surg 119 : 21 ~ 26 [2000]
  • Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma
    de Perrot M J Thorac Cardiovasc Surg 119 21-26 [2000]
  • Parameters for individualizing systemic therapy in non-small cell lung cancer
    Gadgeel SM Drug Resist Updat 13 : 196 ~ 204 [2010]
  • Parameters for individualizing systemic therapy in non-small cell lung cancer
    Gadgeel SM Drug Resist Updat 13 196-204 [2010]
  • Non-small cell lung cancer
    Ettinger DS J Natl Compr Canc Netw 8 : 740 ~ 801 [2010]
  • Non-small cell lung cancer
    Ettinger DS J Natl Compr Canc Netw 8 740-801 [2010]
  • Managed care, hospice use, site of death, and medical expenditures in the last year of life
    Emanuel EJ Arch Intern Med 162 : 1722 ~ 1728 [2002]
  • Managed care, hospice use, site of death, and medical expenditures in the last year of life
    Emanuel EJ Arch Intern Med 162 1722-1728 [2002]
  • Maintenance erlotinib in advanced nonsmall cell lung cancer : cost-effectiveness in EGFR wild-type across Europe
    Walleser S Clinicoecon Outcomes Res 4 : 269 ~ 275 [2012]
  • Maintenance erlotinib in advanced nonsmall cell lung cancer : cost-effectiveness in EGFR wild-type across Europe
    Walleser S Clinicoecon Outcomes Res 4 269-275 [2012]
  • Health care costs in the last week of life : associations with end-of-life conversations
    Zhang B Arch Intern Med 169 : 480 ~ 488 [2009]
  • Health care costs in the last week of life : associations with end-of-life conversations
    Zhang B Arch Intern Med 169 480-488 [2009]
  • Global cancer statistics
    Jemal A CA Cancer J Clin 61 : 69 ~ 90 [2011]
  • Global cancer statistics
    Jemal A CA Cancer J Clin 61 69-90 [2011]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 : 121 ~ 128 [2010]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 121-128 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 : 2380 ~ 2388 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 2380-2388 [2010]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 : 947 ~ 957 [2009]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 947-957 [2009]
  • Female-male differences in patients with primary lung cancer
    McDuffie HH Cancer 59 : 1825 ~ 1830 [1987]
  • Female-male differences in patients with primary lung cancer
    McDuffie HH Cancer 59 1825-1830 [1987]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 : 239 ~ 246 [2012]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 239-246 [2012]
  • Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer : a real-world cost-effectiveness analysis
    Cromwell I Lung Cancer 76 : 472 ~ 477 [2012]
  • Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer : a real-world cost-effectiveness analysis
    Cromwell I Lung Cancer 76 472-477 [2012]
  • Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
    Vergnenegre A Clinicoecon Outcomes Res 4 : 31 ~ 37 [2012]
  • Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
    Vergnenegre A Clinicoecon Outcomes Res 4 31-37 [2012]
  • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Shaw AT N Engl J Med 368 : 2385 ~ 2394 [2013]
  • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Shaw AT N Engl J Med 368 2385-2394 [2013]
  • Cost of care for elderly cancer patients in the United States
    Yabroff KR J Natl Cancer Inst 100 : 630 ~ 641 [2008]
  • Cost of care for elderly cancer patients in the United States
    Yabroff KR J Natl Cancer Inst 100 630-641 [2008]
  • Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer : a systematic review
    Bongers ML Pharmacoeconomics 30 : 17 ~ 34 [2012]
  • Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer : a systematic review
    Bongers ML Pharmacoeconomics 30 17-34 [2012]
  • Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study(GFPC 0505)
    Chouaid C Clin Lung Cancer 14 : 103 ~ 107 [2013]
  • Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study(GFPC 0505)
    Chouaid C Clin Lung Cancer 14 103-107 [2013]
  • Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
    Lee JK Cancer 118 : 3579 ~ 3586 [2012]
  • Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
    Lee JK Cancer 118 3579-3586 [2012]
  • Cancer statistics, 2012
    Siegel R CA Cancer J Clin 62 : 10 ~ 29 [2012]
  • Cancer statistics, 2012
    Siegel R CA Cancer J Clin 62 10-29 [2012]
  • An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    Horgan AM Ann Oncol 22 : 1805 ~ 1811 [2011]
  • An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    Horgan AM Ann Oncol 22 1805-1811 [2011]